Genus Plc News - GNS

Securities Registration Statement (simplified Form) (s-3)

As filed with the Securities and Exchange Commission on January 20, 2021 Registration No. 333- ...

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference Live video webcast...

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq...

Current Report Filing (8-k)

0001729427 false 0001729427 2022-01-10 2022-01-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference PR Newswire HOUSTON, Jan. 7, 2022...

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules PR...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event

CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event Live moderated video webcast...

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme

LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a...

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Genus Plc (GNS)

Professional-Grade Tools, for Individual Investors.

GNS News

Securities Registration Statement (simplified Form) (s-3)

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Current Report Filing (8-k)

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Statement of Changes in Beneficial Ownership (4)

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Statement of Changes in Beneficial Ownership (4)

CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)

Current Report Filing (8-k)

CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook

Quarterly Report (10-q)

GNS Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Genus Plc (GNS) News

Genus Plc (GNS)

Professional-Grade Tools, for Individual Investors.

GNS News

Securities Registration Statement (simplified Form) (s-3)

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Current Report Filing (8-k)

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Statement of Changes in Beneficial Ownership (4)

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Statement of Changes in Beneficial Ownership (4)

CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)

Current Report Filing (8-k)

CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook

Quarterly Report (10-q)

GNS Discussion

Your Recent History